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Abstract: Because sildenaﬁ  l citrate is a treatment, not a cure, for erectile dysfunction (ED), 
many men may choose to use it for an extended period. Men with ED who had previously 
completed 1 of 4 double-blind trials with short-term open-label extension (combined duration, 
0.9–1.2 years) were eligible for this 4-year, open-label, extension study, which assessed the 
safety and effectiveness of ﬂ  exible doses (25, 50, and 100 mg sildenaﬁ  l) used as needed. Adverse 
events that were serious or led to dosing changes or discontinuation (temporary or permanent) 
were recorded. Many of the 979 participants (mean age, 58 [range, 27–82] years; mean ED dura-
tion, 4.5 years) had concomitant hypertension (28%), diabetes (22%), or hyperlipidemia (14%). 
Overall, 37 (3.8%) had treatment-related adverse events (none serious) requiring dosage change 
or discontinuation and 62 (6.3%) discontinued because of insufﬁ  cient response. At each yearly 
assessment, more than 94% of participants responded afﬁ  rmatively to the questions: “Are you 
satisﬁ  ed with the effect of treatment on your erections?” and “If yes, has treatment improved 
your ability to engage in sexual activity?” These results argue against the loss of tolerability or 
the development of tachyphylaxis over a prolonged period of as needed, ﬂ  exible-dose sildenaﬁ  l 
treatment of men with ED.
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Introduction
In March 1998, the US Food and Drug Administration (FDA) approved sildenaﬁ  l citrate 
(Viagra®, Pﬁ  zer Inc, New York, NY, USA) for the treatment of erectile dysfunction (ED) 
(FDA 1998). As of December 2005, more than 27 million men worldwide had received 
sildenaﬁ  l for treatment of ED, including an estimated 17 million men in the US (Data on 
ﬁ  le, Pﬁ  zer Inc, New York, NY). Thus, the long-term safety and effectiveness of sildenaﬁ  l 
can now be evaluated in men who have been taking the drug for several years.
The efﬁ  cacy, safety, and tolerability of sildenaﬁ  l in the treatment of men with ED 
have been demonstrated in numerous studies of 1-year duration or less. For example, 
1,358 men with ED completed 1 of 4 double-blind trials and continued with open-label 
sildenaﬁ  l treatment in extension studies for a total treatment duration of approximately 
1 year (Morales et al 1998; Steers et al 2001). In the current study, 979 of these men 
subsequently received up to 4 more years of open-label, ﬂ  exible-dose (25, 50, and 
100 mg) sildenaﬁ  l. Preliminary (3-year) results were reported previously (Carson et al 
2002; Padma-Nathan et al 2002), and we now present the ﬁ  nal data. The population 
included patients with ED of organic and psychogenic etiology and typical concomitant 
medical conditions for this population (ie, hypertension, diabetes, hyperlipidemia, and 
a history of ischemic heart disease). Our objective was to assess the long-term safety 
and effectiveness of sildenaﬁ  l treatment in men with ED.
Methods
This was a 4-year, open-label, ﬂ  exible-dose (25, 50, and 100 mg) study of sildenaﬁ  l. 
Men who previously completed and were compliant with sildenaﬁ  l or placebo Therapeutics and Clinical Risk Management 2007:3(6) 976
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treatment in 1 of 4 double-blind, placebo-controlled trials, 
and subsequently completed and were compliant with silde-
naﬁ  l treatment in initial open-label extension, were eligible 
for inclusion in this long-term extension study. Study medi-
cation was provided at no cost. Compliance was assessed by 
medication diaries and by continued study participation.
A total of 1,545 men were originally enrolled in the 
double-blind trials, with 1,358 of these men continuing in 
the initial open-label extension studies. The current study 
includes 979 of the original patients, who agreed to partici-
pate in the long-term extension (Figure 1). The procedures 
were in accordance with the ethical standards of the respon-
sible committee on human experimentation (institutional or 
regional).
At the time the study started, the FDA stated that there 
were sufﬁ  cient routine safety data on sildenaﬁ  l to make 
collection of standard adverse event data unnecessary. 
Therefore, only serious adverse events and adverse events 
leading to changes in dosing or to temporary or permanent 
discontinuation were recorded and evaluated by the investi-
gators for relatedness to sildenaﬁ  l treatment.
Because the major focus of this study was safety, and it was 
designed before the development and validation of patient-
reported outcomes to assess satisfaction with the quality of 
erection (eg, Quality of Erection Questionnaire (Porst et al 
2007)) or satisfaction with ED treatment (eg, the Erectile 
Dysfunction Inventory of Treatment Satisfaction (Althof 
et al 1999)), effectiveness was assessed by asking, at yearly 
intervals or at discontinuation, simple, unvalidated general 
efﬁ  cacy questions, “Are you satisﬁ  ed with the effect of treat-
ment on your erections?” and “If yes, has treatment improved 
your ability to engage in sexual activity?” The second ques-
tion was based on the ED deﬁ  nition of the National Institutes 
of Health Consensus Conference: “…inability to attain and/or 
maintain penile erection sufﬁ  cient for satisfactory sexual 
performance.” (NIH Consensus Conference. Impotence. 
Figure 1 Number of patients and treatment duration in the original double-blind trials and the initial open-label extensions and disposition throughout 4 years of open-label, 
ﬂ  exible-dose (25, 50, and 100 mg) sildenaﬁ  l long-term extension study. Of the 979 participants who entered the sildenaﬁ  l long-term extension study, 584 (60%) completed all 
4 years. Reasons for discontinuation, other than insufﬁ  cient clinical response and treatment-related adverse event (AE), included AE unrelated to treatment, protocol violation, 
loss to follow-up, and other (eg, loss of interest in participation in a clinical study, loss of sexual partner, and ability to afford sildenaﬁ  l after approval [thus, no longer needing 
to participate in a clinical study to obtain the medication]). N for the satisfaction question (“Are you satisﬁ  ed with the effect of treatment on your erections?”) is equal to the 
number of men who answered. *Some of the discontinued subjects supplied satisfaction data.Therapeutics and Clinical Risk Management 2007:3(6) 977
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NIH Consensus Development Panel on Impotence 1993). 
Descriptive statistics were calculated.
Results
Overall, 979 men initially agreed to participate in the study, 
most of whom were white (89%) and whose mean age 
was 58 years (Table 1). The duration of the double-blind 
trials plus initial open-label extension was 0.9 to 1.2 years 
(48–60 weeks). Median duration of participation in the open-
label, long-term extension study was 4 years, the median 
number of doses taken was 420 (range, 1–1469) (Figure 2), 
and the preferred dose was 100 mg in more than 88% of the 
men. The retention rate was 84% (818/979) the ﬁ  rst year, 
75% (731/979) the second year, and 66% (648/979) the 
third year; the entire 4-year extension study was completed 
by 584 of the initial 979 men (60%) (Figure 1). Reasons for 
discontinuation included loss of interest in participation in a 
clinical study, loss of sexual partner, loss to follow-up, ability 
to afford sildenaﬁ  l after approval (thus, no longer needing 
to participate in a clinical study to obtain the medication), 
insufﬁ  cient clinical response, and adverse events.
Tolerability
Over the 4-year study period, 37 (3.8%) of the men had 1 or 
more adverse events that led to changes in dosing or to tem-
porary or permanent discontinuation and were determined 
by the investigators to be treatment-related (Table 2). Of 
the 47 events, headache and dyspepsia were most common 
(n = 10 each), followed by rhinitis (n = 6), ﬂ  ushing (n = 5), 
abnormal vision (n = 4), dizziness (n = 3), and 1 report each 
of mild palpitations, moderate tachycardia, diarrhea, nausea, 
myalgia, hypertonia, respiratory disorder, conjunctivitis, and 
photophobia. Of the few cardiovascular events determined by 
the investigator to be treatment related (4 cases of mild 
ﬂ  ushing and 1 each of moderate ﬂ  ushing, mild palpitations, 
and moderate tachycardia), only 1 led to permanent discon-
tinuation. In this case the man experienced mild ﬂ  ushing with 
the ﬁ  rst dose of sildenaﬁ  l 100 mg but continued therapy after 
a dose reduction. After 629 days of therapy, at which time his 
dosage was once again 100 mg, he permanently discontinued 
sildenaﬁ  l because of the ﬂ  ushing. Two other cardiovascular 
events led to temporary discontinuation (mild ﬂ  ushing and 
moderate tachycardia), and the remainder were addressed 
with a change in dosing. Of the 149 serious adverse events 
that occurred during the 4 years of the study, including 
18 acute myocardial infarctions, none were considered by 
the investigator to be treatment related.
Each treatment year, less than 1% of the men who started 
the year discontinued sildenaﬁ  l because of treatment-related 
adverse events, for a total of only 11 (1.1%) of the original 
979 participants over the 4 years of the study (Table 3). 
Discontinuations were caused by dyspepsia (n = 4), rhinitis 
(n = 2), abnormal vision plus headache (n = 1), dyspepsia 
plus rhinitis (n = 1), and ﬂ  ushing, dizziness, and myalgia 
(n = 1 each).
Effectiveness
Of the 979 men who participated in the study, 932 (95%) 
were analyzed for efﬁ  cacy. At the completion of each year, at 
least 94% of the annually decreasing number of participants 
reported satisfaction with the effect of sildenaﬁ  l treatment 
on their erections, with only a 3.3 percentage point variation 
across the 4 yearly assessments (Table 4). Almost all of these 
men reported improved ability to engage in sexual activity.
Each treatment year, less than 3% of the men who started 
the year discontinued sildenaﬁ  l treatment because of insuf-
ﬁ  cient clinical response. Over the 4 years of the study, only 
62 (6.3%) of the original 979 participants discontinued 
because of insufﬁ  cient response (Table 3).
Discussion
There are numerous data published on the efﬁ  cacy and safety 
of sildenaﬁ  l treatment for ED. Before approval, sildenaﬁ  l was 
evaluated in 18 phase II/III double-blind, placebo-controlled 
trials, in which men with ED were randomized to receive 
treatment with sildenaﬁ  l (n = 2722) or placebo (n = 1552) 
for up to 6 months (Morales et al 1998). Pooled data from 
these trials demonstrated that sildenaﬁ  l is a well-tolerated 
oral therapy for ED (Morales et al 1998). Adverse events 
were mostly transient and mild to moderate in severity and 
included most commonly headache, ﬂ  ushing, dyspepsia, and 
rhinitis. The rate of discontinuation because of adverse events 
Table 1 Baseline characteristics of the 979 men
Age, mean (range) years  58.2 (27–82)
Weight, mean (range) kg  89.2 (53.5–158.8)
Race, n (%) 
White 873  (89.2)
Black 68  (6.9)
Asian 8  (0.8)
Other 30  (3.1)
ED duration, mean (range) years  4.5 (0.1–35.8)
ED etiology, % organic/mixed/psychogenic  72/17/11
Common concomitant medical conditions, n (%)
Hypertension 272  (27.8)
Diabetes mellitus  213 (21.8)
Hyperlipidemia 139  (14.2)
History of ischemic heart disease  83 (8.5)Therapeutics and Clinical Risk Management 2007:3(6) 978
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was low and comparable between patients who received 
sildenaﬁ  l and those who received placebo. A more recent 
retrospective analysis, in which data were pooled from 35 
Pﬁ  zer-sponsored double-blind trials involving 4819 patients 
who received sildenaﬁ  l and 3296 patients who received 
placebo, supports the conclusions of the earlier pooled 
data but also found that sildenaﬁ  l is well tolerated among 
patients taking antihypertensive medications, including 
those on multidrug regimens (Padma-Nathan et al 2002). 
Pooled data also support the efﬁ  cacy of sildenaﬁ  l; results 
Figure 2 Usage of ﬂ  exible-dose (25, 50, and 100 mg) sildenaﬁ  l over 2–1561 days by the 979 participants who entered the study.
Table 2 Adverse events that led to changes in dosing or to temporary or permanent discontinuation
  Adverse events (AEs) in 979 men
 Treatment-relateda All  causality
Patients with AEs, n (%)  37 (3.8)  210 (21.5)
Discontinued because of AEs, n (%)  11 (1.1)  55 (5.6)
Most frequent (0.5%) AEs, n (%)   
Headache  10 (1.0)  10 (1.0)
Dyspepsia 10  (1.0)  12  (1.2)
Rhinitis 6  (0.6)  6  (0.6)
Flushing 5  (0.5)  5  (0.5)
Coronary artery disorder  0  24 (2.5)
Prostatic disorder  0  16 (1.6)
Carcinoma 0  14  (1.4)
Myocardial infarction  0  11 (1.1)b
Arthritis 0  9  (0.9)
Bone fracture accidental  0  9 (0.9)
Accidental injury  0  7 (0.7)
Cerebrovascular disorder  0  7 (0.7)
Atrial ﬁ  brillation  0  6 (0.6)
Cholecystitis 0  6  (0.6)
Sepsis 0  5  (0.5)
Heart failure  0  5 (0.5)
Gastrointestinal carcinoma  0  5 (0.5)
Bone disorder  0  5 (0.5)
aOther treatment-related AEs were abnormal vision (n = 4), dizziness (n = 3), and 1 report each of mild palpitations, moderate tachycardia, diarrhea, nausea, myalgia, hypertonia, 
respiratory disorder, conjunctivitis, and photophobia.
bBecause serious adverse events are collected for a longer period (30 days after the completion of treatment) than adverse events in general, numbers of events may vary 
between these 2 databases.Therapeutics and Clinical Risk Management 2007:3(6) 979
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from 11 double-blind, ﬂ  exible-dose, placebo-controlled trials 
that included a total of 2,667 men ages 23 to 89 years with 
ED of broad-spectrum etiology show signiﬁ  cantly improved 
erectile function for sildenaﬁ  l compared with placebo as 
measured by the International Index of Erectile Function, a 
global efﬁ  cacy question, and a patient-recorded event log of 
sexual activity (Carson et al 2002).
The population of the current 4-year open-label study 
of sildenaﬁ  l differed from those of the pooled double-blind 
studies in that it was self-selected. Consequently, it is likely 
that men with poor tolerability or inadequate effectiveness did 
not opt to participate and that the population included mostly 
men who had previously experienced a good response to silde-
naﬁ  l. Also, men who could afford to purchase sildenaﬁ  l may 
have lost incentive to participate in the long-term study when 
sildenaﬁ  l became commercially available. This phenomenon 
necessitated discontinuation of a European long-term OL 
study when sildenaﬁ  l became commercially availabile in 
Europe (Padma-Nathan et al 2001). Another limitation was 
the use of unvalidated general efﬁ  cacy questions, explained 
by the fact that the major focus of the study was safety and 
by the absence at the time of the study design of appropriate 
validated questionnaires to assess satisfaction with ED treat-
ment. Regardless, the results add to the previously published 
reports by showing continued safety and effectiveness during 
prolonged treatment. During 4 years of open-label, ﬂ  exible-
dose administration, there were few discontinuations because 
of either intolerable adverse events or insufﬁ  cient clinical 
response. The majority of men were satisﬁ  ed with sildenaﬁ  l 
treatment for their ED and reported improved ability to engage 
in sexual activity. Throughout the 4-year study period, the 
consistently low incidence of adverse events of sufﬁ  cient 
severity to negatively impact treatment argues against the 
loss of tolerability with time, and the low rate of discontinua-
tion because of insufﬁ  cient clinical response (3% per year) 
argues against the development of tachyphylaxis. The broad 
usage range (1–1469 doses over 4 years) demonstrates the 
“real world” experience provided by the study.
Despite a preferred sildenaﬁ  l dose of 100 mg (the highest 
recommended dose) in more than 88% of the men, treatment-
related cardiovascular adverse events necessitating changes 
in dosing or temporary or permanent discontinuation were 
limited to one case each of mild palpitations and tachycardia 
and 5 cases of ﬂ  ushing. There were no treatment-related acute 
myocardial infarctions or other serious adverse events. Only 
1.1% of participants discontinued treatment over 4 years 
because of treatment-related adverse events, which were most 
frequently dyspepsia, rhinitis, and headache. In comparison, 
treatment-related adverse events were responsible for dis-
continuation by 1.2% of men treated with sildenaﬁ  l 100 mg 
in 6-month, double-blind, placebo-controlled trials (Morales 
et al 1998) and by 2% of 1008 men enrolled in 36-week or 
52-week, open-label extension studies (Steers et al 2001). 
Adverse events were responsible for similarly low rates of 
discontinuation in clinical practice studies of varying dura-
tion conducted worldwide; in California 2.7% of 74 men 
discontinued (Marks et al 1999), in Brazil none of 256 men 
discontinued (Moreira et al 2000), and in China none of 
1,290 men discontinued (Jiann et al 2003). Among 22,471 
men treated with sildenaﬁ  l in general practice in the UK, 
headache was the most frequently reported treatment-related 
adverse event and was cited as the reason for discontinuation 
in 0.3% of men (Boshier et al 2004).
Table 3 Discontinuations over 4 years
  Percentage of participants who discontinued, (n/N)a
Study year  Treatment-related  Insufﬁ  cient response  Other reasons (not
  adverse event    treatment related)
1  0.5 (5/979)  2.2 (22/979)  13.7 (134/979)
2  0.2 (2/818)  2.3 (19/818)  8.1 (66/818)
3  0.1 (1/731)  1.9 (14/731)  9.3 (68/731)
4  0.5 (3/648)  1.1 (7/648)  8.3 (54/648)
aN = the number of men who began the study year.
Table 4 Sildenaﬁ  l treatment outcome over 4 years
  Percentage of participants (n/N)a
Study year  Satisﬁ  ed with treatment  Improved ability to
  effect on erections  have sexual activity
  End of year  End of year
1 98.1  (806/822)  99.6  (803/806)
2 96.6  (672/696)  99.9  (671/672)
3 94.8  (551/581)  99.6  (549/551)
4 96.3  (550/571)  100  (550/550)
aFor the satisfaction analyses, N is equal to the number of men who answered the 
satisfaction question. For the respective sexual activity analyses, N is equal to the 
number of men who answered the satisfaction question afﬁ  rmatively and answered 
the sexual activity question.Therapeutics and Clinical Risk Management 2007:3(6) 980
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The satisfaction with the effectiveness of sildenaﬁ  l for 
the treatment of ED that was reported in the current study 
conﬁ  rms previous results. In one multicenter, open-label 
study, 176 men with ED completed the validated Erectile 
Dysfunction Inventory of Treatment Satisfaction (EDITS) 
questionnaire after long-term successful intracavernosal 
prostaglandin E1 and again 12 weeks after switching to 
ﬂ  exible-dose oral sildenaﬁ  l (25, 50, and 100 mg) (Montorsi 
et al 2003). Sildenaﬁ  l treatment was associated with signiﬁ  -
cantly greater overall treatment satisfaction, ease of use, and 
intention to continue treatment. Moreover, partners were 
more satisﬁ  ed with sildenaﬁ  l overall, and their responses 
correlated with the satisfaction of the patients. Other well-
controlled studies using EDITS have shown similarly high 
degrees of satisfaction with sildenaﬁ  l (Eardley et al 2004; 
Lewis et al 2001).
Conclusions
In this 4-year, open-label study, there was a low incidence of 
adverse events that resulted in dosage change or discontinu-
ation, and most continuing participants were satisﬁ  ed with 
sildenaﬁ  l treatment for their ED. These data are consistent 
with previous reports and argue against loss of tolerability 
or development of tachyphylaxis.
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